12 Best Growth Stocks to Buy and Hold for the Long Term

9. argenx SE (NASDAQ:ARGX)

5-Year Sales Growth: 105.96%

Number of Hedge Fund Holders: 47

argenx SE (NASDAQ:ARGX) is a commercial-stage biotechnology company that focuses on developing antibody therapeutics for autoimmune diseases and cancer. It uses its proprietary discovery platform to leverage unique characteristics of the llama immune system and engineer antibody medicines. Its lead products, VYVGART and VYVGART HYTRULO, are approved in the United States, Europe, and Japan.

On May 9, Douglas Tsao, an analyst at H.C. Wainwright, reiterated a Buy rating on the stock with a price target of $720. The analyst noted the company grew net product sales for VYVGART, which exceeded market expectations. The company reported its fiscal first quarter results for 2025 on May 8. Management noted that it generated a total operating income of $807 million, driven primarily by $790 million in product net sales, which represents a 99% increase compared to the same quarter in the previous year. The product sales of argenx SE (NASDAQ:ARGX) were geographically diversified, with the majority of sales coming from the US.

The analyst, Tsao, noted that the upcoming launch of Vyvgart’s prefilled syringe (PFS), expected to improve patient accessibility and convenience. Management of the company also expects that the self-injection is expected to further expand patient access by enabling easier self-administration and reaching new patient populations. argenx SE (NASDAQ:ARGX) ranks as one of the best growth stocks to buy and hold for the long term.

Artisan Small Cap Fund stated the following regarding Argenx SE (NASDAQ:ARGX) in its Q4 2024 investor letter:

“We ended our investment campaigns in Argenx SE (NASDAQ:ARGX), Tyler Technologies and Interparfums. Shares of Argenx have continued their year-to-date ascent due to multiple positive developments, including FDA approval to promote VYVGART® for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and strong sales execution of VYVGART®’s first approved indication in myasthenia gravis. While we continue to have high conviction, the company has outgrown our small-cap mandate, and we exited our position after a successful multiyear investment campaign.”